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and S. Todo 
D URING the last 5 years, intestinal transplantation has become a feasible therapeutic option for patients 
who have irreversible intestinal failure under tacrolimus 
(FK 506)-based immunosuppression.1- 3 Although there 
was no mortality in adults during the first 2 years after 
initiation of our intestinal transplantation program, survival 
rates worsened rapidly over the last 3 years. In this article, 
we analyze the main contributing factors for the deteriora-
tion of patient and graft outcome after adult intestinal 
transplantation. 
MATERIALS AND METHODS 
From May 1990 to September 1995, 33 intestinal transplantations 
have been performed in 31 adult patients with a mean age of 33.7 
years (19 to 58 years). Sixteen patients received isolated intestinal 
transplantation (small bowel transplantation [SBT]), 9 received 
combined Iiver/SBT, and 6 received multivisceral transplantation 
(MVT). Eleven recipients received a portion of the colon as a part 
of their intestinal graft. In the most recent three patients. donor 
bone marrow was infused at the time of transplantation in an 
attempt to augment microchimerism. The major indication for 
transplantation was intestinal failure resulting from splanchnic 
vascular thrombosis (n = 9), Crohn's disease (n = 7), trauma (n = 
5), desmoid tumor (n = 4), adhesion (n = 2), and others (n = 4). 
Donor and recipient procedures are described elsewhere.4 Postop-
erative immunosuppression was with tacrolimus (FK 506), steroids, 
and in selected cases azathioprine. 
Intestinal allograft rejection was monitored using clinical, endo-
scopic, and histopathologic parameters. Acute graft rejection was 
treated either by augmenting FK 506 therapy, steroid bolus, steroid 
recycle, or OKT3 based on the severity of the rejection episode. 
Recovery of intestinal graft function was assessed primarily by 
serial gastrointestinal (GI) radiographs, FK 506 oral pharmacoki. 
netics, and D-xylose absorption test.5 
Kaplan·Meier and log rank tests were used for statistical analysis 
of survival. Statistical significance was achieved if the P value was 
less than .05. 
j RESULTS 
Fourteen of 31 recipients (42%) are currently alive 1 to 62 
months after intestinal transplantation. Actuarial patient 
and graft survival were 73% and 60% at 1 year, 59% and 
44% at 2 years, and 39% and 29% at 4 years, respectively. 
The main causes of death were sepsis or multiorgan system 
failure (n = 5), pneumonia or adult respiratory distress 
syndrome (ARDS) (n = 5), hepatitis C (n = 2), other 
infections (n = 2), and posttransplant lymphoproliferative 
disorder (n = 1). The major causes of graft failure were 
acute rejection (n = 5), cytomegalovirus (CMV) infection 
(n = 3), ARDS or pneumonia (n = 3), chronic rejection 
(n = 2), and hepatitis C (n = 2). 
Survival was analyzed hy type of intestinal transplanta-
tion. Four-year patient and graft survival were 27% and 
13% in isolated intestinal transplantation, 45% and 45% in 
combined liver/SBT, and 50% and 43% in MVf. Although 
no statistical differences were found among each group, 
primary small bowel grafts tended to have lower survival 
rates than primary liver/SBT and MVf grafts. Of special 
note, graft loss from CMV and rejection were only found in 
the isolated small bowel recipients. 
A total of seven primary grafts were removed in isolated 
intestinal recipients. The reasons for graft removal were 
acute rejection (n = 4), chronic rejection (n = 1), CMV 
infection (n = 1), and pneumonia (n = 1). Of seven 
patients, three are alive on total parenteral nutrition (TPN), 
two died, and two undelWent retransplantation but died 
eventually. 
Cytomegalovirus infection was a significant problem, 
especially for patients receiving an isolated intestinal graft. 
Fourteen recipients (45%) developed CMV disease. Pa-
tients who received CMV -seropositive intestinal grafts had 
significantly worse patient survival than those who received 
CMV-seronegative grafts (P = .047). Four-year actuarial 
patient survival of the patients receiving CMV-seronegative 
was 57% compared with 17% 4-year survival of patients 
receiving CMV-seropositive grafts. Persistent CMV disease 
was found more frequently in isolated intestinal transplan-
tation recipients. 
The inclusion of the colon in the intestinal graft also 
contributed to the worsening graft outcome. Two-year 
actuarial patient survival rates of the patients receiving 
intestinal grafts with and without colon were 36% and 73%, 
respectively (P = .055). Two-year actuarial graft survival 
rates of the patients receiving intestinal grafts with and 
without colon were 25% and 54%, respectively (P = .042). 
Of eight patients who arc alive and at home with 
functioning grafts, seven (85%) are completely free from 
TPN and enjoy an unrestricted oral diet. One patient 
requires partial TPN at night because of rapid motility of 
GI tract. 
DISCUSSION 
The worsening outcome over the past 5 years demanded 
that new strategies be developed to overcome the complex· 
ities of intestinal transplantation. The survival analysis from 
31 adult recipients shows the risk of CMV seropositive 
donor and the inclusion of the colon. The high incidence of 
persistent CMV enteritis in adult isolated intestinal recipi-
ents seems to he the major contrihuting factor to the worse 
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graft survival after isolated intestinal transplantation com-
pared with the other procedures. We believe that the 
outcome after transplantation can be significantly improved 
by avoiding CMV-seropositive grafts, excluding the donor 
colon from the intestinal graft, avoiding extremely difficult 
cases. and by adding other immunosuppressive drugs (such 
as cyclophosphamide or mycophenolate mofetil) in combi-
nation with FK 506.6 Also, long-term survival could be 
improved by enhancing graft acceptance by infusion of 
donor bone marrow to augment microchimerism, although 
it is too early to assess the results. 
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